Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC)

/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid...

Related Keywords

Sweden ,California ,United States ,San Diego ,Stockholm ,Uppsala ,Uppsala Lan ,Swedish ,Oskar Bosson ,Gunilla Osswald ,Uppsala University ,Vp Communications ,Alzheimer Association International Conference ,National Institutes Of Health ,National Institute On ,Drug Administration ,Alzheimer Clinical Trial Consortium ,Nasdaq Stockholm ,Association International Conference ,Biologics License Application ,Prescription Drug User Fee Act ,Pacific Time ,Presentation Number ,Developing Topics ,Infusion Reactions ,Randomized Phase ,Open Label Extension ,Diverse Participant Recruitment ,Disease Prevention Trial ,Autopsy Findings ,Received Long Term Treatment ,Dose Selection ,Early Alzheimer ,Fixed Subcutaneous Dose ,Interaction Characteristics Between Amyloid ,Clinical Benefits ,Elenbecestat Early Alzheimer ,Clinical Trial Consortium ,National Institute ,National Institutes ,Breakthrough Therapy ,Commercialization Agreement ,Nasdaq Stockholm Mid Cap ,Bioarctic ,